SCHEMBL57080

SCHEMBL57080

c1ncc2cscc2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8874014 0.69 EGFR (0.58)
SCHEMBL127479 0.67 EGFR (0.50)
SCHEMBL5065970 0.65 CLK1 (0.39)
SCHEMBL29865299 0.65 EGFR (0.50)
SCHEMBL6119198 0.65 EGFR (0.50)
Quinazoline SCHEMBL8042610 0.64 EGFR (0.77)
SCHEMBL28003243 0.64 EGFR (0.48)
SCHEMBL16536790 0.64 DYRK1A (0.39)
SCHEMBL137377 0.63 EGFR (0.60)
Quinazoline SCHEMBL29490398 0.63 EGFR (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634174-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-10-22 EP claimed
WO-2024129600-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. (US) 2024-06-20 WO claimed
EP-3431484-A1 A FLUORESCENT CYCLIC DINUCLEOTIDE AND ITS USE IN METHODS OF IDENTIFYING SUBSTANCES HAVING AN ABILITY TO MODULATE THE CGAS/STING PATHWAY Ludwig-Maximilians-Universität München (DE) 2019-01-23 EP claimed
CN-1118468-C Pyrazolopyrimidines and pyrazolotriazines HOFFMANN LA ROCHE (CH) 2003-08-20 CN claimed
CN-1236780-A Pyrazolopyrimidines and pyrazolotriazines HOFFMANN LA ROCHE (CH) 1999-12-01 CN claimed
US-3931204-A CARDIOVASCULAR U.C.B. SOCIETE ANONYME (BE) 1976-01-06 US claimed
EP-4707390-A1 LINKER PeptiDream Inc. (JP) 2026-03-11 EP disclosed
EP-4077344-B1 METHODS OF SEQUENCING BY SYNTHESIS USING A CONSECUTIVE LABELING SCHEME HOFFMANN LA ROCHE (CH) 2025-07-23 EP disclosed
WO-2025101722-A1 HIGH-AFFINITY ENGINEERED CHROMODOMAINS AXOIYA INC. (US) 2025-05-15 WO disclosed
WO-2025064825-A1 DNA LIGASE COMPOSITIONS, METHODS, AND USES THEREOF REVISION BIO CORPORATION (US) 2025-03-27 WO disclosed
WO-2025064811-A1 DNA-DEPENDENT DNA POLYMERASE COMPOSITIONS, METHODS, AND USES THEREOF REVISION BIO CORPORATION (US) 2025-03-27 WO disclosed
WO-2024225483-A1 LINKER ペプチドリーム株式会社 2024-10-31 WO disclosed
CN-114829368-B Method for sequencing by synthesis using a continuous labelling scheme 豪夫迈·罗氏有限公司 2024-06-04 CN disclosed
US-4670560-A VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1987-06-02 US disclosed
EP-0008408-B1 1,2,3,5-TETRAHYDROIMIDAZOTHIENOPYRIMIDIN-2-ONES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS DAIICHI SEIYAKU CO., LTD. (JP) 1981-12-09 EP disclosed
US-4284773-A ANTICOAGULANTS DAIICHI SEIYAKU CO., LTD. (JP) 1981-08-18 US disclosed
EP-0008408-A1 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions DAIICHI SEIYAKU CO., LTD. (JP) 1980-03-05 EP disclosed
US-3931204-A CARDIOVASCULAR U.C.B. SOCIETE ANONYME (BE) 1976-01-06 US disclosed
US-3931204-A CARDIOVASCULAR U.C.B. SOCIETE ANONYME (BE) 1976-01-06 US disclosed
US-3931204-A CARDIOVASCULAR U.C.B. SOCIETE ANONYME (BE) 1976-01-06 US disclosed